A Study of GLB-001
Phase 1
48
about 2.7 years
18+
8 sites in CA, KS, NY +1
What this study is about
This trial is testing a new treatment called GLB-001 in people with leukemia or myelodysplastic syndromes that have returned after treatment. The goal is to see if this medication is safe and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GLB-001
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-limiting Toxicity (DLT), Incidence of Adverse Events (AEs), Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD), Recommended Phase 2 Dose (RP2D)
Secondary: CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS), CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML, CR with Partial Hematological Recovery (CRh) Rate in Participants with AML, Complete Remission (CR) Rate in Participants with AML, DOR in Participants with HR-MDS, Duration of Remission or Response (DOR) in Participants with AML, GLB-001 Pharmacokinetics-AUC0-24, GLB-001 Pharmacokinetics-AUC0-last
Oncology